Table 2.
Laboratory characteristics of patients at baseline and after three-month rosuvastatin therapy
|
Diabetic patients (n = 10) |
Hypercholesterolemic patients (n = 10) |
|||||
|---|---|---|---|---|---|---|
| baseline | treatment | #P | baseline | treatment | #P | |
| TC (mg/dl) |
223.7 ± 34.0 |
168.5 ± 45.9 |
0.003 |
288.2 ± 41.0 |
165.5 ± 24.4 |
<0.001 |
| TG (mg/dl) |
165.3 ± 73.0 |
118.5 ± 31.5 |
0.012 |
180.9 ± 61.4 |
133.5 ± 58.9 |
0.004 |
| HDL-c (mg/dl) |
50.0 ± 2.8 |
50.2 ± 6.5 |
0.94 |
55.1 ± 9.9 |
50.7 ± 12.1 |
0.164 |
| LDL-c (mg/dl) |
135.7 ± 20.6 |
85.0 ± 25.6 |
<0.001 |
197.0 ± 34.1 |
88.1 ± 25.1 |
<0.001 |
| ApoA (mg/dl) |
128.0 ± 53.0 |
163.0 ± 14.4 |
0.69 |
144.5 ± 28.5 |
160.1 ± 55.4 |
0.34 |
| ApoB (mg/dl) |
117.2 ± 29.1 |
54.0 ± 14.9 |
<0.001 |
147.1 ± 38.8 |
75.1 ± 24.6 |
<0.001 |
| Glucose (mg/dl) |
137.7 ± 19.4 |
135.5 ± 31.8 |
0.79 |
98.6 ± 5.7 |
97.0 ± 12.9 |
0.77 |
| Insulinemia (ng/ml) |
14.2 ± 3.4 |
16.3 ± 3.5 |
0.63 |
18.8 ± 14.7 |
19.7 ± 17.0 |
0.63 |
| AST |
24.2 ± 4.3 |
24.0 ± 4.1 |
0.94 |
18.3 ± 5.6 |
17.1 ± 3.5 |
0.658 |
| ALT |
37.7 ± 19.2 |
39.2 ± 27.1 |
0.78 |
27.6 ± 12.9 |
21.3 ± 4.4 |
0.122 |
| GGT |
43.3 ± 27.2 |
46.5 ± 39.6 |
0.65 |
21.7 ± 5.9 |
20.1 ± 5.6 |
0.131 |
| CK |
226.8 ±113.7 |
212.7 ± 103.5 |
0.73 |
135.7 ± 64.9 |
134.4 ± 56.6 |
0.994 |
| s-creatinine |
0.98 ± 0.11 |
0.97 ± 0.10 |
0.89 |
0.98 ± 0.17 |
0.99 ± 0.18 |
0.597 |
| GFR |
76.33 ± 12.18 |
77.5 ± 3.56 |
0.79 |
73.22 ± 33.31 |
74.00 ± 12.09 |
0.667 |
| hsCRP | 2.94 ± 2.02 | 1.76 ± 0.51 | 0.03 | 1.70 ± 1.69 | 1.15 ± 0.79 | 0.350 |
TC = total cholesterol; TG = triglycerides; HDL-c = high density lipoprotein-cholesterol; LDL-c = low density lipoprotein-cholesterol; ApoA = Apolipoprotein A; ApoB = Apolipoprotein B; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = γ-glutamyl transpeptidase; CK = creatine kinase; GFR = glomerular filtration rate; hsCRP = high sensitivity C reactive protein. # Paired t test.